Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5.

White BS, Lanc I, O'Neal J, Gupta H, Fulton RS, Schmidt H, Fronick C, Belter EA Jr, Fiala M, King J, Ahmann GJ, DeRome M, Mardis ER, Vij R, DiPersio JF, Levy J, Auclair D, Tomasson MH.

Blood Cancer J. 2018 Mar 21;8(3):35. doi: 10.1038/s41408-018-0062-y.

2.

NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma.

Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F.

Leukemia. 2017 Jul;31(7):1648-1650. doi: 10.1038/leu.2017.115. Epub 2017 Apr 12. No abstract available.

3.

Sabotaging of the oxidative stress response by an oncogenic noncoding RNA.

Mahajan N, Wu HJ, Bennett RL, Troche C, Licht JD, Weber JD, Maggi LB Jr, Tomasson MH.

FASEB J. 2017 Feb;31(2):482-490. doi: 10.1096/fj.201600654R. Epub 2016 Oct 24.

4.

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Welch JS, Petti AA, Miller CA, Fronick CC, O'Laughlin M, Fulton RS, Wilson RK, Baty JD, Duncavage EJ, Tandon B, Lee YS, Wartman LD, Uy GL, Ghobadi A, Tomasson MH, Pusic I, Romee R, Fehniger TA, Stockerl-Goldstein KE, Vij R, Oh ST, Abboud CN, Cashen AF, Schroeder MA, Jacoby MA, Heath SE, Luber K, Janke MR, Hantel A, Khan N, Sukhanova MJ, Knoebel RW, Stock W, Graubert TA, Walter MJ, Westervelt P, Link DC, DiPersio JF, Ley TJ.

N Engl J Med. 2016 Nov 24;375(21):2023-2036. doi: 10.1056/NEJMoa1605949.

5.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W.

Cancer Epidemiol Biomarkers Prev. 2016 Dec;25(12):1609-1618. Epub 2016 Sep 1.

6.

Collaborative Control of Cell Cycle Progression by the RNA Exonuclease Dis3 and Ras Is Conserved Across Species.

Snee MJ, Wilson WC, Zhu Y, Chen SY, Wilson BA, Kseib C, O'Neal J, Mahajan N, Tomasson MH, Arur S, Skeath JB.

Genetics. 2016 Jun;203(2):749-62. doi: 10.1534/genetics.116.187930. Epub 2016 Mar 30.

7.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F.

Clin Cancer Res. 2016 Aug 15;22(16):4206-4214. doi: 10.1158/1078-0432.CCR-15-2793. Epub 2016 Mar 22.

8.

Ex Vivo and In Vivo Evaluation of Overexpressed VLA-4 in Multiple Myeloma Using LLP2A Imaging Agents.

Soodgupta D, Zhou H, Beaino W, Lu L, Rettig M, Snee M, Skeath J, DiPersio JF, Akers WJ, Laforest R, Anderson CJ, Tomasson MH, Shokeen M.

J Nucl Med. 2016 Apr;57(4):640-5. doi: 10.2967/jnumed.115.164624. Epub 2016 Jan 7.

9.

Deletion of Rb1 induces both hyperproliferation and cell death in murine germinal center B cells.

He Z, O'Neal J, Wilson WC, Mahajan N, Luo J, Wang Y, Su MY, Lu L, Skeath JB, Bhattacharya D, Tomasson MH.

Exp Hematol. 2016 Mar;44(3):161-5.e4. doi: 10.1016/j.exphem.2015.11.006. Epub 2015 Dec 1.

10.

Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.

Pan D, Pham CT, Weilbaecher KN, Tomasson MH, Wickline SA, Lanza GM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jan-Feb;8(1):85-106. doi: 10.1002/wnan.1355. Epub 2015 Aug 21. Review.

11.

Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types.

Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, Vachon CM, Colditz G, Vij R, Weilbaecher KN, Tomasson MH.

PLoS One. 2015 May 28;10(5):e0127828. doi: 10.1371/journal.pone.0127828. eCollection 2015.

12.

Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.

Soodgupta D, Pan D, Cui G, Senpan A, Yang X, Lu L, Weilbaecher KN, Prochownik EV, Lanza GM, Tomasson MH.

Mol Cancer Ther. 2015 Jun;14(6):1286-1294. doi: 10.1158/1535-7163.MCT-14-0774-T. Epub 2015 Mar 30.

13.

Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.

Fiala MA, Finney JD, Stockerl-Goldstein KE, Tomasson MH, DiPersio JF, Vij R, Wildes TM.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1153-4. doi: 10.1016/j.bbmt.2015.03.005. Epub 2015 Mar 11.

14.

Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.

Fiala MA, Finney JD, Liu J, Stockerl-Goldstein KE, Tomasson MH, Vij R, Wildes TM.

Leuk Lymphoma. 2015;56(9):2643-9. doi: 10.3109/10428194.2015.1011156. Epub 2015 Mar 8.

15.

A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.

Pan D, Kim B, Hu G, Gupta DS, Senpan A, Yang X, Schmieder A, Swain C, Wickline SA, Tomasson MH, Lanza GM.

Nanomedicine (Lond). 2015 Jan;10(2):241-51. doi: 10.2217/nnm.14.101.

16.

SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution.

Miller CA, White BS, Dees ND, Griffith M, Welch JS, Griffith OL, Vij R, Tomasson MH, Graubert TA, Walter MJ, Ellis MJ, Schierding W, DiPersio JF, Ley TJ, Mardis ER, Wilson RK, Ding L.

PLoS Comput Biol. 2014 Aug 7;10(8):e1003665. doi: 10.1371/journal.pcbi.1003665. eCollection 2014 Aug.

17.

The skinny on obesity and plasma cell myeloma: a review of the literature.

Carson KR, Bates ML, Tomasson MH.

Bone Marrow Transplant. 2014 Aug;49(8):1009-15. doi: 10.1038/bmt.2014.71. Epub 2014 May 12. Review.

PMID:
24820216
18.

Influence of body mass index on survival in veterans with multiple myeloma.

Beason TS, Chang SH, Sanfilippo KM, Luo S, Colditz GA, Vij R, Tomasson MH, Dipersio JF, Stockerl-Goldstein K, Ganti A, Wildes T, Carson KR.

Oncologist. 2013;18(10):1074-9. doi: 10.1634/theoncologist.2013-0015. Epub 2013 Sep 18.

19.

Germinal center B-cells resist transformation by Kras independently of tumor suppressor Arf.

Mullins CD, Su MY, Hucthagowder V, Chu L, Lu L, Kulkarni S, Novack D, Vij R, Tomasson MH.

PLoS One. 2013 Jun 25;8(6):e67941. doi: 10.1371/journal.pone.0067941. Print 2013.

20.

The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

Wang TF, Ahluwalia R, Fiala MA, Trinkaus KM, Cox DP, Jaenicke M, Moliske CC, Carson KR, Wildes TM, Tomasson MH, Stockerl-Goldstein KE, Vij R.

Leuk Lymphoma. 2014 Feb;55(2):337-41. doi: 10.3109/10428194.2013.803547. Epub 2013 Jun 24.

21.

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A, Hoadley K, Triche TJ Jr, Laird PW, Baty JD, Fulton LL, Fulton R, Heath SE, Kalicki-Veizer J, Kandoth C, Klco JM, Koboldt DC, Kanchi KL, Kulkarni S, Lamprecht TL, Larson DE, Lin L, Lu C, McLellan MD, McMichael JF, Payton J, Schmidt H, Spencer DH, Tomasson MH, Wallis JW, Wartman LD, Watson MA, Welch J, Wendl MC, Ally A, Balasundaram M, Birol I, Butterfield Y, Chiu R, Chu A, Chuah E, Chun HJ, Corbett R, Dhalla N, Guin R, He A, Hirst C, Hirst M, Holt RA, Jones S, Karsan A, Lee D, Li HI, Marra MA, Mayo M, Moore RA, Mungall K, Parker J, Pleasance E, Plettner P, Schein J, Stoll D, Swanson L, Tam A, Thiessen N, Varhol R, Wye N, Zhao Y, Gabriel S, Getz G, Sougnez C, Zou L, Leiserson MD, Vandin F, Wu HT, Applebaum F, Baylin SB, Akbani R, Broom BM, Chen K, Motter TC, Nguyen K, Weinstein JN, Zhang N, Ferguson ML, Adams C, Black A, Bowen J, Gastier-Foster J, Grossman T, Lichtenberg T, Wise L, Davidsen T, Demchok JA, Shaw KR, Sheth M, Sofia HJ, Yang L, Downing JR, Eley G.

N Engl J Med. 2013 May 30;368(22):2059-74. doi: 10.1056/NEJMoa1301689. Epub 2013 May 1. Erratum in: N Engl J Med. 2013 Jul 4;369(1):98.

22.

Very late antigen-4 (α(4)β(1) Integrin) targeted PET imaging of multiple myeloma.

Soodgupta D, Hurchla MA, Jiang M, Zheleznyak A, Weilbaecher KN, Anderson CJ, Tomasson MH, Shokeen M.

PLoS One. 2013;8(2):e55841. doi: 10.1371/journal.pone.0055841. Epub 2013 Feb 8. Erratum in: PLoS One. 2013;8(8). doi:10.1371/annotation/8532e291-73d3-461c-810d-0533ccb1eba0.

23.

Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.

Hucthagowder V, Meyer R, Mullins C, Nagarajan R, DiPersio JF, Vij R, Tomasson MH, Kulkarni S.

Cancer Genet. 2012 Sep;205(9):474-8. doi: 10.1016/j.cancergen.2012.06.007.

24.

The origin and evolution of mutations in acute myeloid leukemia.

Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, Dooling DJ, Wallis JW, Chen K, Harris CC, Schmidt HK, Kalicki-Veizer JM, Lu C, Zhang Q, Lin L, O'Laughlin MD, McMichael JF, Delehaunty KD, Fulton LA, Magrini VJ, McGrath SD, Demeter RT, Vickery TL, Hundal J, Cook LL, Swift GW, Reed JP, Alldredge PA, Wylie TN, Walker JR, Watson MA, Heath SE, Shannon WD, Varghese N, Nagarajan R, Payton JE, Baty JD, Kulkarni S, Klco JM, Tomasson MH, Westervelt P, Walter MJ, Graubert TA, DiPersio JF, Ding L, Mardis ER, Wilson RK.

Cell. 2012 Jul 20;150(2):264-78. doi: 10.1016/j.cell.2012.06.023.

25.

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.

Hurchla MA, Garcia-Gomez A, Hornick MC, Ocio EM, Li A, Blanco JF, Collins L, Kirk CJ, Piwnica-Worms D, Vij R, Tomasson MH, Pandiella A, San Miguel JF, Garayoa M, Weilbaecher KN.

Leukemia. 2013 Feb;27(2):430-40. doi: 10.1038/leu.2012.183. Epub 2012 Jul 5.

26.

Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress.

Chu L, Su MY, Maggi LB Jr, Lu L, Mullins C, Crosby S, Huang G, Chng WJ, Vij R, Tomasson MH.

J Clin Invest. 2012 Aug;122(8):2793-806. doi: 10.1172/JCI63051. Epub 2012 Jul 2.

27.

Molecular-targeted therapies for hematologic malignancies.

Bunting KD, Qu CK, Tomasson MH.

Adv Hematol. 2012;2012:606423. doi: 10.1155/2012/606423. Epub 2011 Dec 28. No abstract available.

28.

Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, Shen D, Harris CC, Dooling DJ, Fulton RS, Fulton LL, Chen K, Schmidt H, Kalicki-Veizer J, Magrini VJ, Cook L, McGrath SD, Vickery TL, Wendl MC, Heath S, Watson MA, Link DC, Tomasson MH, Shannon WD, Payton JE, Kulkarni S, Westervelt P, Walter MJ, Graubert TA, Mardis ER, Wilson RK, DiPersio JF.

Nature. 2012 Jan 11;481(7382):506-10. doi: 10.1038/nature10738.

29.

Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes.

Graubert TA, Shen D, Ding L, Okeyo-Owuor T, Lunn CL, Shao J, Krysiak K, Harris CC, Koboldt DC, Larson DE, McLellan MD, Dooling DJ, Abbott RM, Fulton RS, Schmidt H, Kalicki-Veizer J, O'Laughlin M, Grillot M, Baty J, Heath S, Frater JL, Nasim T, Link DC, Tomasson MH, Westervelt P, DiPersio JF, Mardis ER, Ley TJ, Wilson RK, Walter MJ.

Nat Genet. 2011 Dec 11;44(1):53-7. doi: 10.1038/ng.1031.

30.

Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.

Welch JS, Westervelt P, Ding L, Larson DE, Klco JM, Kulkarni S, Wallis J, Chen K, Payton JE, Fulton RS, Veizer J, Schmidt H, Vickery TL, Heath S, Watson MA, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Ley TJ, Wilson RK.

JAMA. 2011 Apr 20;305(15):1577-84. doi: 10.1001/jama.2011.497.

31.

Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression.

Wartman LD, Larson DE, Xiang Z, Ding L, Chen K, Lin L, Cahan P, Klco JM, Welch JS, Li C, Payton JE, Uy GL, Varghese N, Ries RE, Hoock M, Koboldt DC, McLellan MD, Schmidt H, Fulton RS, Abbott RM, Cook L, McGrath SD, Fan X, Dukes AF, Vickery T, Kalicki J, Lamprecht TL, Graubert TA, Tomasson MH, Mardis ER, Wilson RK, Ley TJ.

J Clin Invest. 2011 Apr;121(4):1445-55. doi: 10.1172/JCI45284. Epub 2011 Mar 23.

32.

DNMT3A mutations in acute myeloid leukemia.

Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK.

N Engl J Med. 2010 Dec 16;363(25):2424-33. doi: 10.1056/NEJMoa1005143. Epub 2010 Nov 10.

33.

CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity.

Cheng M, Zhou J, Wu M, Boriboun C, Thorne T, Liu T, Xiang Z, Zeng Q, Tanaka T, Tang YL, Kishore R, Tomasson MH, Miller RJ, Losordo DW, Qin G.

Circ Res. 2010 Oct 29;107(9):1083-93. doi: 10.1161/CIRCRESAHA.110.220970. Epub 2010 Sep 16.

34.

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, Tomasson MH.

J Clin Invest. 2010 Jun;120(6):2109-18. doi: 10.1172/JCI39964. Epub 2010 May 17.

35.

Recurring mutations found by sequencing an acute myeloid leukemia genome.

Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ.

N Engl J Med. 2009 Sep 10;361(11):1058-66. doi: 10.1056/NEJMoa0903840. Epub 2009 Aug 5.

36.

Acquired copy number alterations in adult acute myeloid leukemia genomes.

Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O'Gara BP, Bloomfield CD, Mrózek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12950-5. doi: 10.1073/pnas.0903091106. Epub 2009 Jul 27.

37.

Cancer stem cells: a guide for skeptics.

Tomasson MH.

J Cell Biochem. 2009 Apr 1;106(5):745-9. doi: 10.1002/jcb.22050. Review.

PMID:
19184979
38.

Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple myeloma.

O'Neal J, Gao F, Hassan A, Monahan R, Barrios S, Kilimann MW, Lee I, Chng WJ, Vij R, Tomasson MH.

Exp Hematol. 2009 Feb;37(2):234-44. doi: 10.1016/j.exphem.2008.10.014. Erratum in: Exp Hematol. 2009 Apr;37(4):532. Kilimann, Manfred W [added].

39.

Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.

Uy GL, Goyal SD, Fisher NM, Oza AY, Tomasson MH, Stockerl-Goldstein K, DiPersio JF, Vij R.

Bone Marrow Transplant. 2009 May;43(10):793-800. doi: 10.1038/bmt.2008.384. Epub 2008 Nov 24.

PMID:
19029964
40.

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome.

Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K, Dooling D, Dunford-Shore BH, McGrath S, Hickenbotham M, Cook L, Abbott R, Larson DE, Koboldt DC, Pohl C, Smith S, Hawkins A, Abbott S, Locke D, Hillier LW, Miner T, Fulton L, Magrini V, Wylie T, Glasscock J, Conyers J, Sander N, Shi X, Osborne JR, Minx P, Gordon D, Chinwalla A, Zhao Y, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson M, Baty J, Ivanovich J, Heath S, Shannon WD, Nagarajan R, Walter MJ, Link DC, Graubert TA, DiPersio JF, Wilson RK.

Nature. 2008 Nov 6;456(7218):66-72. doi: 10.1038/nature07485.

41.

Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

Liu F, Kunter G, Krem MM, Eades WC, Cain JA, Tomasson MH, Hennighausen L, Link DC.

J Clin Invest. 2008 Mar;118(3):946-55. doi: 10.1172/JCI32704.

42.

Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.

Tomasson MH, Xiang Z, Walgren R, Zhao Y, Kasai Y, Miner T, Ries RE, Lubman O, Fremont DH, McLellan MD, Payton JE, Westervelt P, DiPersio JF, Link DC, Walter MJ, Graubert TA, Watson M, Baty J, Heath S, Shannon WD, Nagarajan R, Bloomfield CD, Mardis ER, Wilson RK, Ley TJ.

Blood. 2008 May 1;111(9):4797-808. doi: 10.1182/blood-2007-09-113027. Epub 2008 Feb 12.

43.

The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.

Blood. 2008 Apr 1;111(7):3751-9. doi: 10.1182/blood-2007-07-102186. Epub 2008 Jan 23.

44.

Bortezomib inhibits osteoclast activity in patients with multiple myeloma.

Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH, DiPersio JF, Vij R.

Clin Lymphoma Myeloma. 2007 Nov;7(9):587-9.

PMID:
18186967
45.

Identification of somatic JAK1 mutations in patients with acute myeloid leukemia.

Xiang Z, Zhao Y, Mitaksov V, Fremont DH, Kasai Y, Molitoris A, Ries RE, Miner TL, McLellan MD, DiPersio JF, Link DC, Payton JE, Graubert TA, Watson M, Shannon W, Heath SE, Nagarajan R, Mardis ER, Wilson RK, Ley TJ, Tomasson MH.

Blood. 2008 May 1;111(9):4809-12. Epub 2007 Dec 26.

46.

Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ.

Blood. 2007 Sep 1;110(5):1648-55. Epub 2007 May 9.

47.

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

Cain JA, Xiang Z, O'Neal J, Kreisel F, Colson A, Luo H, Hennighausen L, Tomasson MH.

Blood. 2007 May 1;109(9):3906-14. Epub 2007 Jan 11.

48.

Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.

Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH.

Mol Cell Biol. 2007 Jan;27(1):267-82. Epub 2006 Oct 23.

49.

The activity and toxicity of low dose clofarabine against relapsed or refractory myeloma.

Uy GL, Tomasson MH, Ruddell A, DiPersio JF, Vij R.

Haematologica. 2006 Nov;91(11):1581-2. Epub 2006 Oct 17.

50.

c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.

Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH.

Blood. 2005 Oct 1;106(7):2452-61. Epub 2005 Jun 21.

Supplemental Content

Loading ...
Support Center